Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 450 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/02
End: 02/29/08
Due: 02/28/09
Phase: N/A
Priority: Normal
Start: 07/09/18
End: 02/07/26
Due: 02/07/27
Phase: N/A
Priority: Normal
Start: 04/16/11
End: 10/05/15
Due: 10/05/16
Phase: N/A
Priority: Normal
Start: 11/28/17
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 10/31/97
End: 07/31/01
Due: 07/31/02
Phase: N/A
Priority: Normal
Start: 11/20/23
End: 09/01/27
Due: 09/01/28
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase: N/A
Priority: Normal
Start: 06/30/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/08/18
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 12/31/03
End: 04/30/11
Due: 04/30/12
Phase: N/A
Priority: Normal
Start: 05/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/08/23
End: 01/01/28
Due: 01/01/29
Phase: N/A
Priority: Normal
Start: 05/21/24
End: 01/01/28
Due: 01/01/29
Phase: N/A
Priority: Normal
Start: 03/01/23
End: 09/01/26
Due: 09/01/27
Phase: N/A
Priority: Normal
Start: 08/11/06
End: 12/15/16
Due: 12/15/17
Phase: N/A
Priority: Normal
Start: 02/08/22
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 03/21/23
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 03/01/00
End: 03/30/10
Due: 03/30/11
Phase: N/A
Priority: Normal
Start: 07/31/02
End: 03/31/10
Due: 03/31/11
Phase: N/A
Priority: Normal
Start: 10/31/77
End: 11/30/01
Due: 11/30/02
Phase: N/A
Priority: Normal
Start: 04/30/10
End: 05/31/14
Due: 05/31/15
Phase: N/A
Priority: Normal
Start: 05/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/02
End: 03/31/08
Due: 03/31/09
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 01/31/14
Due: 01/31/15
Phase: N/A
Priority: Normal
Start: 02/28/06
End: 12/31/10
Due: 12/31/11